Cancer Immunotherapy Market
Research Code:MRHC - 1048
Sku:MRHC - 1048
Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), and End User- Global Forecast to 2024
- Report ID: MRHC - 1048
- Pages: 173
- Oct-2018
- Formats*: PDF
- Category: Healthcare
- Delivery: 2 to 4 Hours
We are in the phase of updating this report by analysing the impact of COVID-19 on this market.
The cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to 2024 to reach USD 152.83 billion by 2024. Cancer immunotherapy is a treatment that uses the body’s own immune system to help fight cancer. Cancer cells have the ability to invade the immune system through various mechanisms. Immunotherapy focuses on these mechanisms and develops another mechanism to restore the immune system and its ability to destroy the cancer cells. Rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market are the major factors driving the growth of overall cancer immunotherapy market.
Rising Cancer Incidence Fuels the Growth of the Global Cancer Immunotherapy Market
According to GLOBOCAN 2018, incidence rate of cancer has increased from 14.1 million in 2012 to 15.2 million in 2015 to 17.0 million in 2018 with a rise of about 12%. Moreover, the mortality due to cancer has also witnessed a rise from 8.2 million deaths in 2012 to 9.4 million deaths in 2018. According to American Cancer Society, lung cancer is one of the most common forms of cancer globally. Number of people living with lung cancer is 2.09 million in 2018 which is expected to increase 2.27 million by 2020 (Source: World Health Organization). Over the years, incidence of cancer has increased in developing countries (Asia Pacific and African Countries) and currently account for about 54.2% of cases and 64.7% of cancer deaths worldwide. The rising incidence of cancer in the coming years will increase the adoption of cancer immunotherapies. The increasing survival rate in the patients adopting cancer immunotherapy as a treatment option is expected to boost the growth of the cancer immunotherapy market during the forecast period.
Growing Adoption of Cancer Immunotherapy over Other Treatment Options Supports the Market Growth
Chemotherapy and radiation therapy is most commonly used for treatment of cancer in the current scenario. However, adverse effects associated with these treatments are the major concern among healthcare professionals and patients. Drugs such as keytruda and Opdivo trigger the immune system in order to destroy the oncogenic cells. Immunotherapies help in acting upon the target cell that cannot be captured by the chemotherapeutics and hence selectively attacks the cancer cells only. Owing to this mechanism, the products such as monoclonal antibodies, check point inhibitors, and cell therapies are widely adopted for better efficacy and effective therapeutic actions. Moreover, according to the study (long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor) presented at the American Association for Cancer Research (AACR) in 2017, 16% of patients with advanced NSCLC treated with Nivolumab were alive 5 years after treatment; compares with only about 4% of patients alive at 5 years with conventional chemotherapy. This increase in adoption of the immunotherapies due to its advantages over the traditional therapies and longer-term survival rate is expected to drive the overall cancer immunotherapy market during the forecast period.
Click here to: Get Free Request Sample Copy of this report
Development of Bioinformatics Tools Enhancing Drug Development Process!
The biopharmaceutical companies usually face the challenge during drug development with respect to the selection of protein molecules and drug designing. The development of various bioinformatics tools, such as the Basic Local Alignment Search Tool (BLAST) and European Molecular Biology Open Software Suite (EMBOSS) help researchers to select the appropriate molecule for drug designing. The adoption of these tools has significantly reduced the cost and timeline of drug development process. Utilization of bioinformatics tools as a strategy is one of the most critical and useful approaches to design clinical medicine for clinical research & applications and improve the outcomes of patients with cancer. This tool provides a unique and outstanding platform and opportunity for scientists to integrate omics science, bioinformatics tools & data, clinical research, disease-specific biomarkers, dynamic networks, with precision medicine, together fighting cancer and improving the life quality of patients with cancer. These tools also help in detecting the post-mutational functions of proteins, increasing the probability of successfully developing the drug. This technology is enhancing the interest among the pharmaceutical and biotechnology companies, and research organizations to increase the uptake of research projects for cancer immunotherapy, thereby increasing the investment in cancer immunotherapy market.
Key Findings in the Global Cancer Immunotherapy Market Study:
Multiple Myeloma and Melanoma Applications to Post the Fastest Growth
Cancer immunotherapy has found significant application in the treatment of different types of cancer owing to the advantages provided to patients as compared to the traditional treatment options. The demand for cancer immunotherapy in the treatment of multiple myeloma and melanoma is expected to witness a rapid growth through 2024, mainly due to growing focus on patient safety, increasing the 5 year survival rate of the patients, high adoption of this therapy in multiple myeloma and melanoma, and increasing drug approval of cancer immunotherapies in these cancers. Moreover, recognizing the potential of immunotherapy in multiple myeloma, major players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of multiple myeloma.
Monoclonal Antibodies Dominates Global Cancer Immunotherapy Market
Being awell adopted treatment option for different types of cancer, the monoclonal antibodies held the largest share of the global cancer immunotherapy market in 2017. Moreover, the total number of monoclonal antibodies (mAbs) approved by the US FDA and European Commission has reached 73 in 2017. The number of approved antibodies in a year has significantly increased since 2014 with a steady rise in the next three years. Monoclonal antibody drug development has moved from an early piecemeal stage to a large-scale development phase. In 2017, a total of ten new monoclonal antibodies were approved in mainstream markets around the world, reaching a record high.
Checkpoint Inhibitors to Witness the Largest Demand Through 2023
The checkpoint inhibitors market is to witness the highest growth in the global cancer immunotherapy market in 2017 owing to its high adoption in the treatment of major cancers. Moreover, major players in the cancer immunotherapy market are focusing on development of checkpoint inhibitors for which the companies are collaborating with other players to fasten the development process and access newer technologies. For instance, in 2016, Merck (US) collaborated with Dynavax Technologies Corporation (US) to investigate the potential synergistic effects by combining Dynavax’s SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966.
Asia Pacific: The Fastest Growing Regional Market
The cancer immunotherapy market in Asia Pacific, especially in China, India, and Japan is expected to witness high growth during the forecast period. The growth in this market is expected to be driven by large pool of patient population seeking the cancer treatment, increasing prevalence of cancer, aggressive investment by the major players in the market, increasing government spending on the healthcare, and growing disposable income of the population that improved the access to cancer treatment. Furthermore, the lack of stringent regulations and liberalization in Asian countries is also a factor making Asia Pacific a lucrative market. However, availability of the cancer immunotherapy drugs is limited to the high income group owing to its high price in current scenario. This coupled with the lower coverage of the health insurance in APAC countries as compared to other regions are the key factors restraining the growth of the cancer immunotherapy market in APAC.
Key Players
The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 5 years (2014-2018). The key players profiled in the global cancer immunotherapy market research report are F. Hoffmann-La Roche (Switzerland), Celgene Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), Amgen Inc. (US), ELI Lilly and Company (US), Janssen Global Services, LLC (US) (Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among others.
Scope of the Report:
Market by Product
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Immunomodulators
- Vaccines
- Cell Therapy
Market by Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Multiple Myeloma
- Other Cancer Types
Market by End User
- Hospitals
- Clinics & Others
Market by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
Lung cancer accounted for the largest share of the cancer immunotherapy market globally
- What factors contribute to the frequent usage of cancer immunotherapy products to treat various types of cancer cases?
- Which geographic segment register the highest growth in the usage of cancer immunotherapy products to treat several types of cancers such as lung cancer, breast cancer, and other?
- How does the penetration of cancer immunotherapy products in treatment of lung cancer differ from other application?
North America market favors both regional and local manufacturers that compete in multiple segments
- Which are the top competitors in this market and what strategies do they employ to gain shares?
- What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?
- What strategies should new companies looking to enter in this market use to compete effectively?
- What are the major drivers, restraints, opportunities, and challenges in the cancer immunotherapy market?
- Who are the major players in various countries and what share of the market do they hold?
- What are the geographical trends and high growth regions/ countries?
Recent partnerships, acquisitions, and expansions have taken place in the global cancer immunotherapy market
- What companies have recently merged/acquired and how will these unions affect the competitive landscape of the cancer immunotherapy market?
- What companies have created partnerships and how will these partnerships promote a competitive advantage?
- Who are the major players in the global cancer immunotherapy products market and what share of the market do they hold?
- What are the local emerging players in the global cancer immunotherapy market and how do they compete with the global players?
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer incidence
4.2.2. Growing Adoption of Immunotherapy Over Other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry insights
5.1. Key industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. OPDIVO and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles (Overview, Products and Services, Financials, and Developments)
11.1. AstraZeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis Ag
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Major Cancer Immunotherapy Drugs Approved (2015–2017)
Table 2 Recent Developments for Cancer Immunotherapy Market in China
Table 3 Global Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 4 Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 5 Key Monoclonal Antibodies Approved for Cancer Immunotherapy
Table 6 Key Conjugated Antibodies for Cancer Immunotherapy
Table 7 Monoclonal Antibodies Market Size, by Country/Region, 2016–2024 ($Million)
Table 8 Major FDA Approved Pd-1 and Pd-L1 inhibitors
Table 9 Checkpoint inhibitors Market Size, by Country/Region, 2016–2024 ($Million)
Table 10 Key Immunomodulators Available in The Market
Table 11 Immunomodulators Market Size, by Country/Region, 2016–2024 ($Million)
Table 12 Cancer Vaccines Market Size, by Country/Region, 2016–2024 ($Million)
Table 13 Cell Therapies Market Size, by Country/Region, 2016–2024 ($Million)
Table 14 Global Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 15 Lung Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 16 Breast Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 17 Colorectal Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 18 Melanoma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 19 Prostate Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 20 Multiple Myeloma: Recent Developments from Leading Players
Table 21 Multiple Myeloma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 22 Other Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 23 Global Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 24 Cancer Immunotherapy Market Size for Hospitals, by Country/Region, 2016–2024 ($Million)
Table 25 Cancer Immunotherapy Market Size for Clinics and Others, by Country/Region, 2016–2024 ($Million)
Table 26 North America: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 27 North America: Market Size, by Type, 2016–2024 ($Million)
Table 28 North America: Market Size, by Application, 2016–2024 ($Million)
Table 29 North America: Market Size, by End User, 2016–2024 ($Million)
Table 30 Leading Sites of New Cancer Cases (2017)
Table 31 U.S.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 32 U.S.: Market Size, by Application, 2016–2024 ($Million)
Table 33 U.S.: Market Size, by End User, 2016–2024 ($Million)
Table 34 Canada: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 35 Canada: Market Size, by Application, 2016–2024 ($Million)
Table 36 Canada: Market Size, by End User, 2016–2024 ($Million)
Table 37 Europe: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 38 Europe: Market Size, by Type, 2016–2024 ($Million)
Table 39 Europe: Market Size, by Application, 2016–2024 ($Million)
Table 40 Europe: Market Size, by End User, 2016–2024 ($Million)
Table 41 Germany: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 42 Germany: Market Size, by Application, 2016–2024 ($Million)
Table 43 Germany: Market Size, by End User, 2016–2024 ($Million)
Table 44 France: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 45 France: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 46 France: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 47 U.K.: Funding by National Cancer Research institute, 2012
Table 48 U.K.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 49 U.K.: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 50 U.K.: Cancer Immunotherapy MarketSize, by End User, 2016–2024 ($Million)
Table 51 Italy: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 52 Italy: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 53 Italy: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 54 Spain: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 55 Spain: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 56 Spain: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 57 Rest of Europe: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 58 Rest of Europe: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 59 Rest of Europe: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 60 Asia Pacific: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 61 Asia Pacific: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 62 Asia Pacific: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 63 Asia Pacific: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 64 China: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 65 China: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 66 China: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 67 Japan: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 68 Japan: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 69 Japan: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 70 India: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 71 India: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 72 India: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 73 Rest of APAC: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 74 Rest of APAC: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 75 Rest of APAC: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 76 Latin America: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 77 Latin America: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 78 Latin America: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 79 Middle East and Africa: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 80 Middle East and Africa: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 81 Middle East and Africa: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 82 Key Products: Monoclonal Antibodies
Table 83 Key Products: Checkpoint inhibitors
Table 84 Key Products: Immunomodulators
Table 85 Key Products: Vaccines
Table 86 Key Products: Cell Therapies
List of Figures
Figure 1 Key Stakeholders in The Cancer Immunotherapy Market
Figure 2 Research Process
Figure 3 Key Executives interviewed
Figure 4 Primary Research Techniques
Figure 5 Market Size Estimation
Figure 6 Global Cancer Immunotherapy Market, 2016–2024 ($ Million)
Figure 7 Cancer Immunotherapy Market: Global Market Outlook, by Type 2018 Vs. 2024
Figure 8 Cancer Immunotherapy Market: Global Market Outlook, by Application, 2018 Vs 2024
Figure 9 Cancer Immunotherapy Market: Global Market Outlook, by End User 2018 Vs. 2024
Figure 10 Asia Pacific Region Expected to Witness the Fastest Growth During the Forecast Period
Figure 11 Cancer Immunotherapy: Regional Market Outlook, 2018 Vs 2024
Figure 12 Market Overview: Cancer Immunotherapy Market
Figure 13 Global Cancer incidence and Mortality (2018)
Figure 14 Cancer Therapy Deals Distribution (2012-2016)
Figure 15 Clinical Trials Check Point inhibitors (2017)
Figure 16 R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
Figure 17 Cancer incidence by Region (2018)
Figure 18 Per Capita Healthcare Expenditure in Selected Emerging Countries ($)
Figure 19 Improvement in 5 Year Survival Rates: Personalized Immunotherapy
Figure 20 Biopharmaceutical Companies Are Committed to Advancing Personalized Medicines
Figure 21 Clinical Trials for Cancer Immunotherapy in Combination
Figure 22 OPDIVO (BMS) Vs Keytruda (Merck)
Figure 23 Distribution of Approved Monoclonal Antibody Drugs by indication
Figure 24 Number of Combination Studies for Pd-1/Pd-L1 Mab
Figure 25 Global Cancer Immunotherapy Market Size, by Application, 2018–2024 ($Million)
Figure 26 Lung Cancer Statistics (2018)
Figure 27 Pd-1 & Pd-L1: New Clinical Trials and Average Enrolment Per New Trial
Figure 28 Breast Cancer Statistics (2018)
Figure 29 Colorectal Cancer Statistics (2018)
Figure 30 Melanoma incidence Rate, 2016 (Per 100,000)
Figure 31 Prostate Cancer Statistics (2018)
Figure 32 Global Cancer Immunotherapy Market, by End User, 2018–2024 ($Million)
Figure 33 U.S. Healthcare Spending ($ Billion)
Figure 34 U.S. Healthcare Spending ($ Billion)
Figure 35 U.S.: Country Health Profile (Cancer)
Figure 36 Canada: Cancer incidence by Type (2015)
Figure 37 Canada: Geriatric Population (Million)
Figure 38 Canada: Country Profile (Cancer)
Figure 39 Europe: Highest Share of Geriatric Population, 2010-2017
Figure 40 Germany: Country Health Profile (Cancer)
Figure 41 France: Country Health Profile
Figure 42 U.K.: Country Health Profile
Figure 43 Italy: Country Health Profile
Figure 44 Spain: Share of Clinical Trials in Oncology
Figure 45 Spain: Country Health Profile
Figure 46 Rest of Europe: Key indicators
Figure 47 China: Clinical Trials (2012–2016)
Figure 48 China: Country Health Profile
Figure 49 Japan: Country Health Profile
Figure 50 India: Country Health Profile
Figure 51 Australia: Country Health Profile
Figure 52 Brazil: Country Health Profile
Figure 53 Key Strategies Adopted by Major Players in The Market: Approvals
Figure 54 Market Share Analysis (2017)
Figure 55 Cancer Immunotherapy: Competitive Benchmarking
This website is secure and we do not share your personal information with any third party. Privacy Policy
The cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to 2024 to reach USD 152.83 billion by 2024. Cancer immunotherapy is a treatment that uses the body’s own immune system to help fight cancer. Cancer cells have the ability to invade the immune system through various mechanisms. Immunotherapy focuses on these mechanisms and develops another mechanism to restore the immune system and its ability to destroy the cancer cells. Rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market are the major factors driving the growth of overall cancer immunotherapy market.
Rising Cancer Incidence Fuels the Growth of the Global Cancer Immunotherapy Market
According to GLOBOCAN 2018, incidence rate of cancer has increased from 14.1 million in 2012 to 15.2 million in 2015 to 17.0 million in 2018 with a rise of about 12%. Moreover, the mortality due to cancer has also witnessed a rise from 8.2 million deaths in 2012 to 9.4 million deaths in 2018. According to American Cancer Society, lung cancer is one of the most common forms of cancer globally. Number of people living with lung cancer is 2.09 million in 2018 which is expected to increase 2.27 million by 2020 (Source: World Health Organization). Over the years, incidence of cancer has increased in developing countries (Asia Pacific and African Countries) and currently account for about 54.2% of cases and 64.7% of cancer deaths worldwide. The rising incidence of cancer in the coming years will increase the adoption of cancer immunotherapies. The increasing survival rate in the patients adopting cancer immunotherapy as a treatment option is expected to boost the growth of the cancer immunotherapy market during the forecast period.
Growing Adoption of Cancer Immunotherapy over Other Treatment Options Supports the Market Growth
Chemotherapy and radiation therapy is most commonly used for treatment of cancer in the current scenario. However, adverse effects associated with these treatments are the major concern among healthcare professionals and patients. Drugs such as keytruda and Opdivo trigger the immune system in order to destroy the oncogenic cells. Immunotherapies help in acting upon the target cell that cannot be captured by the chemotherapeutics and hence selectively attacks the cancer cells only. Owing to this mechanism, the products such as monoclonal antibodies, check point inhibitors, and cell therapies are widely adopted for better efficacy and effective therapeutic actions. Moreover, according to the study (long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor) presented at the American Association for Cancer Research (AACR) in 2017, 16% of patients with advanced NSCLC treated with Nivolumab were alive 5 years after treatment; compares with only about 4% of patients alive at 5 years with conventional chemotherapy. This increase in adoption of the immunotherapies due to its advantages over the traditional therapies and longer-term survival rate is expected to drive the overall cancer immunotherapy market during the forecast period.
Click here to: Get Free Request Sample Copy of this report
Development of Bioinformatics Tools Enhancing Drug Development Process!
The biopharmaceutical companies usually face the challenge during drug development with respect to the selection of protein molecules and drug designing. The development of various bioinformatics tools, such as the Basic Local Alignment Search Tool (BLAST) and European Molecular Biology Open Software Suite (EMBOSS) help researchers to select the appropriate molecule for drug designing. The adoption of these tools has significantly reduced the cost and timeline of drug development process. Utilization of bioinformatics tools as a strategy is one of the most critical and useful approaches to design clinical medicine for clinical research & applications and improve the outcomes of patients with cancer. This tool provides a unique and outstanding platform and opportunity for scientists to integrate omics science, bioinformatics tools & data, clinical research, disease-specific biomarkers, dynamic networks, with precision medicine, together fighting cancer and improving the life quality of patients with cancer. These tools also help in detecting the post-mutational functions of proteins, increasing the probability of successfully developing the drug. This technology is enhancing the interest among the pharmaceutical and biotechnology companies, and research organizations to increase the uptake of research projects for cancer immunotherapy, thereby increasing the investment in cancer immunotherapy market.
Key Findings in the Global Cancer Immunotherapy Market Study:
Multiple Myeloma and Melanoma Applications to Post the Fastest Growth
Cancer immunotherapy has found significant application in the treatment of different types of cancer owing to the advantages provided to patients as compared to the traditional treatment options. The demand for cancer immunotherapy in the treatment of multiple myeloma and melanoma is expected to witness a rapid growth through 2024, mainly due to growing focus on patient safety, increasing the 5 year survival rate of the patients, high adoption of this therapy in multiple myeloma and melanoma, and increasing drug approval of cancer immunotherapies in these cancers. Moreover, recognizing the potential of immunotherapy in multiple myeloma, major players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of multiple myeloma.
Monoclonal Antibodies Dominates Global Cancer Immunotherapy Market
Being awell adopted treatment option for different types of cancer, the monoclonal antibodies held the largest share of the global cancer immunotherapy market in 2017. Moreover, the total number of monoclonal antibodies (mAbs) approved by the US FDA and European Commission has reached 73 in 2017. The number of approved antibodies in a year has significantly increased since 2014 with a steady rise in the next three years. Monoclonal antibody drug development has moved from an early piecemeal stage to a large-scale development phase. In 2017, a total of ten new monoclonal antibodies were approved in mainstream markets around the world, reaching a record high.
Checkpoint Inhibitors to Witness the Largest Demand Through 2023
The checkpoint inhibitors market is to witness the highest growth in the global cancer immunotherapy market in 2017 owing to its high adoption in the treatment of major cancers. Moreover, major players in the cancer immunotherapy market are focusing on development of checkpoint inhibitors for which the companies are collaborating with other players to fasten the development process and access newer technologies. For instance, in 2016, Merck (US) collaborated with Dynavax Technologies Corporation (US) to investigate the potential synergistic effects by combining Dynavax’s SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966.
Asia Pacific: The Fastest Growing Regional Market
The cancer immunotherapy market in Asia Pacific, especially in China, India, and Japan is expected to witness high growth during the forecast period. The growth in this market is expected to be driven by large pool of patient population seeking the cancer treatment, increasing prevalence of cancer, aggressive investment by the major players in the market, increasing government spending on the healthcare, and growing disposable income of the population that improved the access to cancer treatment. Furthermore, the lack of stringent regulations and liberalization in Asian countries is also a factor making Asia Pacific a lucrative market. However, availability of the cancer immunotherapy drugs is limited to the high income group owing to its high price in current scenario. This coupled with the lower coverage of the health insurance in APAC countries as compared to other regions are the key factors restraining the growth of the cancer immunotherapy market in APAC.
Key Players
The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 5 years (2014-2018). The key players profiled in the global cancer immunotherapy market research report are F. Hoffmann-La Roche (Switzerland), Celgene Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), Amgen Inc. (US), ELI Lilly and Company (US), Janssen Global Services, LLC (US) (Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among others.
Scope of the Report:
Market by Product
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Immunomodulators
- Vaccines
- Cell Therapy
Market by Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Multiple Myeloma
- Other Cancer Types
Market by End User
- Hospitals
- Clinics & Others
Market by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
Lung cancer accounted for the largest share of the cancer immunotherapy market globally
- What factors contribute to the frequent usage of cancer immunotherapy products to treat various types of cancer cases?
- Which geographic segment register the highest growth in the usage of cancer immunotherapy products to treat several types of cancers such as lung cancer, breast cancer, and other?
- How does the penetration of cancer immunotherapy products in treatment of lung cancer differ from other application?
North America market favors both regional and local manufacturers that compete in multiple segments
- Which are the top competitors in this market and what strategies do they employ to gain shares?
- What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?
- What strategies should new companies looking to enter in this market use to compete effectively?
- What are the major drivers, restraints, opportunities, and challenges in the cancer immunotherapy market?
- Who are the major players in various countries and what share of the market do they hold?
- What are the geographical trends and high growth regions/ countries?
Recent partnerships, acquisitions, and expansions have taken place in the global cancer immunotherapy market
- What companies have recently merged/acquired and how will these unions affect the competitive landscape of the cancer immunotherapy market?
- What companies have created partnerships and how will these partnerships promote a competitive advantage?
- Who are the major players in the global cancer immunotherapy products market and what share of the market do they hold?
- What are the local emerging players in the global cancer immunotherapy market and how do they compete with the global players?
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer incidence
4.2.2. Growing Adoption of Immunotherapy Over Other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry insights
5.1. Key industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. OPDIVO and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles (Overview, Products and Services, Financials, and Developments)
11.1. AstraZeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis Ag
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Major Cancer Immunotherapy Drugs Approved (2015–2017)
Table 2 Recent Developments for Cancer Immunotherapy Market in China
Table 3 Global Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 4 Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 5 Key Monoclonal Antibodies Approved for Cancer Immunotherapy
Table 6 Key Conjugated Antibodies for Cancer Immunotherapy
Table 7 Monoclonal Antibodies Market Size, by Country/Region, 2016–2024 ($Million)
Table 8 Major FDA Approved Pd-1 and Pd-L1 inhibitors
Table 9 Checkpoint inhibitors Market Size, by Country/Region, 2016–2024 ($Million)
Table 10 Key Immunomodulators Available in The Market
Table 11 Immunomodulators Market Size, by Country/Region, 2016–2024 ($Million)
Table 12 Cancer Vaccines Market Size, by Country/Region, 2016–2024 ($Million)
Table 13 Cell Therapies Market Size, by Country/Region, 2016–2024 ($Million)
Table 14 Global Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 15 Lung Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 16 Breast Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 17 Colorectal Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 18 Melanoma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 19 Prostate Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 20 Multiple Myeloma: Recent Developments from Leading Players
Table 21 Multiple Myeloma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 22 Other Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 23 Global Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 24 Cancer Immunotherapy Market Size for Hospitals, by Country/Region, 2016–2024 ($Million)
Table 25 Cancer Immunotherapy Market Size for Clinics and Others, by Country/Region, 2016–2024 ($Million)
Table 26 North America: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 27 North America: Market Size, by Type, 2016–2024 ($Million)
Table 28 North America: Market Size, by Application, 2016–2024 ($Million)
Table 29 North America: Market Size, by End User, 2016–2024 ($Million)
Table 30 Leading Sites of New Cancer Cases (2017)
Table 31 U.S.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 32 U.S.: Market Size, by Application, 2016–2024 ($Million)
Table 33 U.S.: Market Size, by End User, 2016–2024 ($Million)
Table 34 Canada: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 35 Canada: Market Size, by Application, 2016–2024 ($Million)
Table 36 Canada: Market Size, by End User, 2016–2024 ($Million)
Table 37 Europe: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 38 Europe: Market Size, by Type, 2016–2024 ($Million)
Table 39 Europe: Market Size, by Application, 2016–2024 ($Million)
Table 40 Europe: Market Size, by End User, 2016–2024 ($Million)
Table 41 Germany: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 42 Germany: Market Size, by Application, 2016–2024 ($Million)
Table 43 Germany: Market Size, by End User, 2016–2024 ($Million)
Table 44 France: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 45 France: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 46 France: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 47 U.K.: Funding by National Cancer Research institute, 2012
Table 48 U.K.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 49 U.K.: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 50 U.K.: Cancer Immunotherapy MarketSize, by End User, 2016–2024 ($Million)
Table 51 Italy: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 52 Italy: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 53 Italy: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 54 Spain: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 55 Spain: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 56 Spain: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 57 Rest of Europe: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 58 Rest of Europe: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 59 Rest of Europe: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 60 Asia Pacific: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 61 Asia Pacific: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 62 Asia Pacific: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 63 Asia Pacific: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 64 China: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 65 China: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 66 China: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 67 Japan: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 68 Japan: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 69 Japan: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 70 India: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 71 India: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 72 India: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 73 Rest of APAC: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 74 Rest of APAC: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 75 Rest of APAC: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 76 Latin America: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 77 Latin America: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 78 Latin America: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 79 Middle East and Africa: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 80 Middle East and Africa: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 81 Middle East and Africa: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 82 Key Products: Monoclonal Antibodies
Table 83 Key Products: Checkpoint inhibitors
Table 84 Key Products: Immunomodulators
Table 85 Key Products: Vaccines
Table 86 Key Products: Cell Therapies
List of Figures
Figure 1 Key Stakeholders in The Cancer Immunotherapy Market
Figure 2 Research Process
Figure 3 Key Executives interviewed
Figure 4 Primary Research Techniques
Figure 5 Market Size Estimation
Figure 6 Global Cancer Immunotherapy Market, 2016–2024 ($ Million)
Figure 7 Cancer Immunotherapy Market: Global Market Outlook, by Type 2018 Vs. 2024
Figure 8 Cancer Immunotherapy Market: Global Market Outlook, by Application, 2018 Vs 2024
Figure 9 Cancer Immunotherapy Market: Global Market Outlook, by End User 2018 Vs. 2024
Figure 10 Asia Pacific Region Expected to Witness the Fastest Growth During the Forecast Period
Figure 11 Cancer Immunotherapy: Regional Market Outlook, 2018 Vs 2024
Figure 12 Market Overview: Cancer Immunotherapy Market
Figure 13 Global Cancer incidence and Mortality (2018)
Figure 14 Cancer Therapy Deals Distribution (2012-2016)
Figure 15 Clinical Trials Check Point inhibitors (2017)
Figure 16 R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
Figure 17 Cancer incidence by Region (2018)
Figure 18 Per Capita Healthcare Expenditure in Selected Emerging Countries ($)
Figure 19 Improvement in 5 Year Survival Rates: Personalized Immunotherapy
Figure 20 Biopharmaceutical Companies Are Committed to Advancing Personalized Medicines
Figure 21 Clinical Trials for Cancer Immunotherapy in Combination
Figure 22 OPDIVO (BMS) Vs Keytruda (Merck)
Figure 23 Distribution of Approved Monoclonal Antibody Drugs by indication
Figure 24 Number of Combination Studies for Pd-1/Pd-L1 Mab
Figure 25 Global Cancer Immunotherapy Market Size, by Application, 2018–2024 ($Million)
Figure 26 Lung Cancer Statistics (2018)
Figure 27 Pd-1 & Pd-L1: New Clinical Trials and Average Enrolment Per New Trial
Figure 28 Breast Cancer Statistics (2018)
Figure 29 Colorectal Cancer Statistics (2018)
Figure 30 Melanoma incidence Rate, 2016 (Per 100,000)
Figure 31 Prostate Cancer Statistics (2018)
Figure 32 Global Cancer Immunotherapy Market, by End User, 2018–2024 ($Million)
Figure 33 U.S. Healthcare Spending ($ Billion)
Figure 34 U.S. Healthcare Spending ($ Billion)
Figure 35 U.S.: Country Health Profile (Cancer)
Figure 36 Canada: Cancer incidence by Type (2015)
Figure 37 Canada: Geriatric Population (Million)
Figure 38 Canada: Country Profile (Cancer)
Figure 39 Europe: Highest Share of Geriatric Population, 2010-2017
Figure 40 Germany: Country Health Profile (Cancer)
Figure 41 France: Country Health Profile
Figure 42 U.K.: Country Health Profile
Figure 43 Italy: Country Health Profile
Figure 44 Spain: Share of Clinical Trials in Oncology
Figure 45 Spain: Country Health Profile
Figure 46 Rest of Europe: Key indicators
Figure 47 China: Clinical Trials (2012–2016)
Figure 48 China: Country Health Profile
Figure 49 Japan: Country Health Profile
Figure 50 India: Country Health Profile
Figure 51 Australia: Country Health Profile
Figure 52 Brazil: Country Health Profile
Figure 53 Key Strategies Adopted by Major Players in The Market: Approvals
Figure 54 Market Share Analysis (2017)
Figure 55 Cancer Immunotherapy: Competitive Benchmarking
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer incidence
4.2.2. Growing Adoption of Immunotherapy Over Other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry insights
5.1. Key industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. OPDIVO and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles (Overview, Products and Services, Financials, and Developments)
11.1. AstraZeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis Ag
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Major Cancer Immunotherapy Drugs Approved (2015–2017)
Table 2 Recent Developments for Cancer Immunotherapy Market in China
Table 3 Global Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 4 Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 5 Key Monoclonal Antibodies Approved for Cancer Immunotherapy
Table 6 Key Conjugated Antibodies for Cancer Immunotherapy
Table 7 Monoclonal Antibodies Market Size, by Country/Region, 2016–2024 ($Million)
Table 8 Major FDA Approved Pd-1 and Pd-L1 inhibitors
Table 9 Checkpoint inhibitors Market Size, by Country/Region, 2016–2024 ($Million)
Table 10 Key Immunomodulators Available in The Market
Table 11 Immunomodulators Market Size, by Country/Region, 2016–2024 ($Million)
Table 12 Cancer Vaccines Market Size, by Country/Region, 2016–2024 ($Million)
Table 13 Cell Therapies Market Size, by Country/Region, 2016–2024 ($Million)
Table 14 Global Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 15 Lung Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 16 Breast Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 17 Colorectal Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 18 Melanoma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 19 Prostate Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 20 Multiple Myeloma: Recent Developments from Leading Players
Table 21 Multiple Myeloma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 22 Other Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 23 Global Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 24 Cancer Immunotherapy Market Size for Hospitals, by Country/Region, 2016–2024 ($Million)
Table 25 Cancer Immunotherapy Market Size for Clinics and Others, by Country/Region, 2016–2024 ($Million)
Table 26 North America: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 27 North America: Market Size, by Type, 2016–2024 ($Million)
Table 28 North America: Market Size, by Application, 2016–2024 ($Million)
Table 29 North America: Market Size, by End User, 2016–2024 ($Million)
Table 30 Leading Sites of New Cancer Cases (2017)
Table 31 U.S.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 32 U.S.: Market Size, by Application, 2016–2024 ($Million)
Table 33 U.S.: Market Size, by End User, 2016–2024 ($Million)
Table 34 Canada: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 35 Canada: Market Size, by Application, 2016–2024 ($Million)
Table 36 Canada: Market Size, by End User, 2016–2024 ($Million)
Table 37 Europe: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 38 Europe: Market Size, by Type, 2016–2024 ($Million)
Table 39 Europe: Market Size, by Application, 2016–2024 ($Million)
Table 40 Europe: Market Size, by End User, 2016–2024 ($Million)
Table 41 Germany: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 42 Germany: Market Size, by Application, 2016–2024 ($Million)
Table 43 Germany: Market Size, by End User, 2016–2024 ($Million)
Table 44 France: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 45 France: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 46 France: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 47 U.K.: Funding by National Cancer Research institute, 2012
Table 48 U.K.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 49 U.K.: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 50 U.K.: Cancer Immunotherapy MarketSize, by End User, 2016–2024 ($Million)
Table 51 Italy: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 52 Italy: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 53 Italy: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 54 Spain: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 55 Spain: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 56 Spain: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 57 Rest of Europe: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 58 Rest of Europe: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 59 Rest of Europe: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 60 Asia Pacific: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 61 Asia Pacific: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 62 Asia Pacific: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 63 Asia Pacific: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 64 China: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 65 China: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 66 China: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 67 Japan: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 68 Japan: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 69 Japan: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 70 India: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 71 India: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 72 India: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 73 Rest of APAC: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 74 Rest of APAC: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 75 Rest of APAC: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 76 Latin America: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 77 Latin America: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 78 Latin America: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 79 Middle East and Africa: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 80 Middle East and Africa: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 81 Middle East and Africa: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 82 Key Products: Monoclonal Antibodies
Table 83 Key Products: Checkpoint inhibitors
Table 84 Key Products: Immunomodulators
Table 85 Key Products: Vaccines
Table 86 Key Products: Cell Therapies
List of Figures
Figure 1 Key Stakeholders in The Cancer Immunotherapy Market
Figure 2 Research Process
Figure 3 Key Executives interviewed
Figure 4 Primary Research Techniques
Figure 5 Market Size Estimation
Figure 6 Global Cancer Immunotherapy Market, 2016–2024 ($ Million)
Figure 7 Cancer Immunotherapy Market: Global Market Outlook, by Type 2018 Vs. 2024
Figure 8 Cancer Immunotherapy Market: Global Market Outlook, by Application, 2018 Vs 2024
Figure 9 Cancer Immunotherapy Market: Global Market Outlook, by End User 2018 Vs. 2024
Figure 10 Asia Pacific Region Expected to Witness the Fastest Growth During the Forecast Period
Figure 11 Cancer Immunotherapy: Regional Market Outlook, 2018 Vs 2024
Figure 12 Market Overview: Cancer Immunotherapy Market
Figure 13 Global Cancer incidence and Mortality (2018)
Figure 14 Cancer Therapy Deals Distribution (2012-2016)
Figure 15 Clinical Trials Check Point inhibitors (2017)
Figure 16 R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
Figure 17 Cancer incidence by Region (2018)
Figure 18 Per Capita Healthcare Expenditure in Selected Emerging Countries ($)
Figure 19 Improvement in 5 Year Survival Rates: Personalized Immunotherapy
Figure 20 Biopharmaceutical Companies Are Committed to Advancing Personalized Medicines
Figure 21 Clinical Trials for Cancer Immunotherapy in Combination
Figure 22 OPDIVO (BMS) Vs Keytruda (Merck)
Figure 23 Distribution of Approved Monoclonal Antibody Drugs by indication
Figure 24 Number of Combination Studies for Pd-1/Pd-L1 Mab
Figure 25 Global Cancer Immunotherapy Market Size, by Application, 2018–2024 ($Million)
Figure 26 Lung Cancer Statistics (2018)
Figure 27 Pd-1 & Pd-L1: New Clinical Trials and Average Enrolment Per New Trial
Figure 28 Breast Cancer Statistics (2018)
Figure 29 Colorectal Cancer Statistics (2018)
Figure 30 Melanoma incidence Rate, 2016 (Per 100,000)
Figure 31 Prostate Cancer Statistics (2018)
Figure 32 Global Cancer Immunotherapy Market, by End User, 2018–2024 ($Million)
Figure 33 U.S. Healthcare Spending ($ Billion)
Figure 34 U.S. Healthcare Spending ($ Billion)
Figure 35 U.S.: Country Health Profile (Cancer)
Figure 36 Canada: Cancer incidence by Type (2015)
Figure 37 Canada: Geriatric Population (Million)
Figure 38 Canada: Country Profile (Cancer)
Figure 39 Europe: Highest Share of Geriatric Population, 2010-2017
Figure 40 Germany: Country Health Profile (Cancer)
Figure 41 France: Country Health Profile
Figure 42 U.K.: Country Health Profile
Figure 43 Italy: Country Health Profile
Figure 44 Spain: Share of Clinical Trials in Oncology
Figure 45 Spain: Country Health Profile
Figure 46 Rest of Europe: Key indicators
Figure 47 China: Clinical Trials (2012–2016)
Figure 48 China: Country Health Profile
Figure 49 Japan: Country Health Profile
Figure 50 India: Country Health Profile
Figure 51 Australia: Country Health Profile
Figure 52 Brazil: Country Health Profile
Figure 53 Key Strategies Adopted by Major Players in The Market: Approvals
Figure 54 Market Share Analysis (2017)
Figure 55 Cancer Immunotherapy: Competitive Benchmarking